For both IDH-mutant grade 2 astrocytomas and oligodendrogliomas, maximal safe resection remains the cornerstone of initial management, with supramarginal resection (SMR) enhancing the feasibility of observation by reducing residual tumor burden and delaying progression, as supported by recent studies (7). The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).